Previous close | 2.5400 |
Open | 2.5900 |
Bid | 2.5700 x 200 |
Ask | 3.3200 x 200 |
Day's range | 2.5300 - 2.9000 |
52-week range | 2.1600 - 4.6500 |
Volume | |
Avg. volume | 81,139 |
Market cap | 348.237M |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.5400 |
Earnings date | 01 Aug 2024 - 05 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.25 |
Explore key financial outcomes and strategic insights from Nautilus Biotechnology's first quarter of 2024, emphasizing growth in expenses and future expectations.
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. “We continued to make solid progress against our core development goals in Q1,” said Sujal Patel, CEO of Nautilus. “We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software
Details on Financial Performance and Strategic Progress Amidst Development Phase